Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...

SAN DIEGO — Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, appears to safely and effectively treat metabolic dysfunction–associated steatohepatitis (MASH) among patients with ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of researchers has now discovered it can also do wonders for people who have ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...